Relapse-free survival from first PCR analysis of patients in CR compared to maximum response to IFN therapy.

One of 27 patients with low levels of residual disease (≤ 0.045% BCR-ABL/ABL) relapsed compared to13 of 27 patients with relatively high levels (> 0.045%, P < .0001, 2-sided logrank test).